[CAS NO. 122956-68-7] (Rac)-Modipafant

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [122956-68-7]

Catalog

HY-108908

Brand

MCE

CAS

122956-68-7

DESCRIPTION [122956-68-7]

Overview

MDL	MFCD00864793
Molecular Weight	605.09
Molecular Formula	C34H29ClN6O3
SMILES	O=C(C1=C(C2=CC=C(N3C(C)=NC4=C3C=CN=C4)C=C2)NC(C)=C(C(NC5=NC=CC=C5)=O)C1C6=CC=CC=C6Cl)OCC

For research use only. We do not sell to patients.

Summary

(Rac)-Modipafant (UK-74505) is an orally active, selective, long-acting irreversible platelet activating factor receptor (PAFR) antagonist. (Rac)-Modipafant prevents dengue infection ^[1] ^[2] ^[3] .

In Vivo

(Rac)-Modipafant (UK-74505) (10 mg/kg; p.o.; twice a day until day 10) prevents Severe Dengue Infection ^[3] .
(Rac)-Modipafant exhibits highly selective, time-dependent inhibition of PAF-induced aggregation of rabbit washed platelets (IC ₅₀ =26.3 and 1.12 nM after 0.25 and 60 min preincubation, respectively) ^[4] .
(Rac)-Modipafant (5-20 mg/kg; p.o.) dose-dependently inhibits the Zymosan -induced articular hyperalgesia ^[5] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	8- to 10-week-old BALB/c mice (DEN-2 strain infected) ^[3]
Dosage:	10 mg/kg
Administration:	P.o.; twice a day (started on days 0, 3, 5, or 7) until day 10
Result:	Decreased by approximately 50% the lethality associated with DEN-2 infection.

Animal Model:	Male BALB/C (8- to 10- week-old) wild-type mice ^[5]
Dosage:	5, 10 and 20 mg/kg
Administration:	P.o.
Result:	Dose-dependently inhibited the Zymosan -induced articular hyperalgesia.

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 82.63 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.6526 mL	8.2632 mL	16.5265 mL
5 mM	0.3305 mL	1.6526 mL	3.3053 mL
10 mM	0.1653 mL	0.8263 mL	1.6526 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (4.13 mM); Clear solution

* All of the co-solvents are available by MCE.